(2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- 2-propenoic acid-2-(2-pyridinyl)hydrazide
Verdinexor (KPT-335)
CAS: 1392136-43-4
Molecular Formula: C18H12F6N6O
(2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- 2-propenoic acid-2-(2-pyridinyl)hydrazide - Names and Identifiers
| Name | Verdinexor (KPT-335) |
| Synonyms | CS-1798 KPT-335 Verdinexor Verdinexor(KPT-335) Verdinexor (KPT-335) Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyridin- (KPT335)(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyridin-2-yl)acrylohydrazide (2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- 2-propenoic acid-2-(2-pyridinyl)hydrazide (2Z)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N -(pyridin-2-yl)prop-2-enehydrazide Verdinexor(KPT-335) |
| CAS | 1392136-43-4 |
(2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- 2-propenoic acid-2-(2-pyridinyl)hydrazide - Physico-chemical Properties
| Molecular Formula | C18H12F6N6O |
| Molar Mass | 442.32 |
| Density | 1.49±0.1 g/cm3(Predicted) |
| pKa | 10.04±0.43(Predicted) |
| Storage Condition | -20℃ |
| In vitro study | Verdinexor inhibits the viability of Jurkat, OCI-Ly3, OCI-Ly10, and CLBL1 cells with IC50 of 0.3 nM, 2.1 nM, 41.8 nM, and 8.5 nM respectively. KPT-335 also induces apoptosis in CLBL1 cells and primary canine DLBCL cells that express XPO1 and SINE. Verdinexor potently and selectively inhibits vRNP export and effectively inhibits the replication of various influenza virus A and B strains, including pandemic H1N1 virus, high pathogenic H5N1 avian influenza virus, and the recent emerging H7N9 strain. Verdinexor inhibited the activity of Jurkat,OCI-Ly3,OCI-Ly10, and CLBL1 cells with an IC50 of 0.3 nM,2.1 nM,41.8 nM, and 8.5 nM, respectively. KPT-335 also induced apoptosis in CLBL1 and primary canine DLBCL cells expressing XPO1 and SINE. Verdinexor selectively potently inhibits vRNP export and also potently inhibits various influenza Virus A and B strains, including pandemic H1N1 Virus, highly pathogenic H5N1 avian influenza Virus, and more recently the H7N9 strain. |
| In vivo study | Verdinexor (25 mg/kg twice daily, p.o.) reduces proinflammatory cytokine expression in the lung, produces in vivo antiviral activity by reducing lung virus titers, and thus reduces pulmonary disease pathogenesis and death associated with lethal influenza A virus challenge. In autosomal-dominant polycystic kidney disease model, Verdinexor (5 mg/kg, I .p.) attenuates cyst growth via inhibition of XPO1. Verdinexor (25 mg/kg twice daily, p.o.) reduces the expression of pro-inflammatory cytokines in the lungs, produces anti-Virus activity in vivo by reducing lung Virus titers, and thus reduces lung disease associated with lethal influenza A A Virus by Incidence Rate and Mortality Rate. In an autosomal dominant polycystic kidney disease model, Verdinexor (5 mg/kg, I. p.) attenuates cyst growth by inhibiting xpo1. |
(2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- 2-propenoic acid-2-(2-pyridinyl)hydrazide - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.261 ml | 11.304 ml | 22.608 ml |
| 5 mM | 0.452 ml | 2.261 ml | 4.522 ml |
| 10 mM | 0.226 ml | 1.13 ml | 2.261 ml |
| 5 mM | 0.045 ml | 0.226 ml | 0.452 ml |
Last Update：2024-01-02 23:10:35
(2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- 2-propenoic acid-2-(2-pyridinyl)hydrazide - Introduction
Verdinexor(KPT-335) is a small molecule compound that is a selective inhibitor of the nuclear transporter protein XPO1.
Verdinexor is mainly used to treat certain types of leukemia and solid tumors. It inhibits the growth and spread of tumors by inhibiting the function of the nuclear transport protein XPO1 and preventing the extra-nuclear transport of certain important proteins in cancer cells.
The preparation method of Verdinexor is generally synthesized by an organic synthesis method. Specific synthetic methods may vary, but organic synthetic chemicals and reagents are usually used to synthesize the compound through a series of reaction steps.
Regarding the safety information of Verdinexor, it should be noted that it may cause some side effects, such as nausea, vomiting, fatigue, etc. In addition, long-term use of Verdinexor may also lead to some other adverse reactions, such as thrombocytopenia, infection and so on. Before using Verdinexor, you should consult your doctor and conduct a relevant safety assessment.
Verdinexor is mainly used to treat certain types of leukemia and solid tumors. It inhibits the growth and spread of tumors by inhibiting the function of the nuclear transport protein XPO1 and preventing the extra-nuclear transport of certain important proteins in cancer cells.
The preparation method of Verdinexor is generally synthesized by an organic synthesis method. Specific synthetic methods may vary, but organic synthetic chemicals and reagents are usually used to synthesize the compound through a series of reaction steps.
Regarding the safety information of Verdinexor, it should be noted that it may cause some side effects, such as nausea, vomiting, fatigue, etc. In addition, long-term use of Verdinexor may also lead to some other adverse reactions, such as thrombocytopenia, infection and so on. Before using Verdinexor, you should consult your doctor and conduct a relevant safety assessment.
Last Update：2024-04-09 20:52:54
![(2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- 2-propenoic acid-2-(2-pyridinyl)hydrazide](http://res.chembk.com/assets/images/structure/1392136-43-4.gif)
Supplier List
Product Name: Verdinexor (KPT-335) Visit Supplier Webpage Request for quotation
CAS: 1392136-43-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 1392136-43-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Verdinexor (KPT-335) Visit Supplier Webpage Request for quotation
CAS: 1392136-43-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 1392136-43-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History